[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

KR960004363A - Pyrimidine Acyclonucleoside Derivatives - Google Patents

Pyrimidine Acyclonucleoside Derivatives Download PDF

Info

Publication number
KR960004363A
KR960004363A KR1019940018324A KR19940018324A KR960004363A KR 960004363 A KR960004363 A KR 960004363A KR 1019940018324 A KR1019940018324 A KR 1019940018324A KR 19940018324 A KR19940018324 A KR 19940018324A KR 960004363 A KR960004363 A KR 960004363A
Authority
KR
South Korea
Prior art keywords
group
pharmaceutically acceptable
formula
acceptable salt
atom
Prior art date
Application number
KR1019940018324A
Other languages
Korean (ko)
Other versions
KR0140021B1 (en
Inventor
김대기
감종식
김강혁
김영우
임진수
김훈택
김기협
Original Assignee
김준웅
주식회사 선경인더스트리
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to KR1019940018324A priority Critical patent/KR0140021B1/en
Application filed by 김준웅, 주식회사 선경인더스트리 filed Critical 김준웅
Priority to BR9408370A priority patent/BR9408370A/en
Priority to EP94922386A priority patent/EP0748316B1/en
Priority to US08/545,682 priority patent/US5889013A/en
Priority to JP7507220A priority patent/JP2683297B2/en
Priority to CA002159817A priority patent/CA2159817C/en
Priority to DE69430587T priority patent/DE69430587T2/en
Priority to AU73512/94A priority patent/AU693107B2/en
Priority to PCT/KR1994/000102 priority patent/WO1995023138A1/en
Publication of KR960004363A publication Critical patent/KR960004363A/en
Application granted granted Critical
Publication of KR0140021B1 publication Critical patent/KR0140021B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/56—One oxygen atom and one sulfur atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

본 발명은 다음 구조식(Ⅰ)로 표시되는 신규한 피리미딘 아사이클로뉴클레오시드 유도체 및 이를 유효성분으로 하는 항바이러스제에 관한 것이다.The present invention relates to a novel pyrimidine acyclonucleoside derivative represented by the following structural formula (I) and an antiviral agent comprising the same as an active ingredient.

상기 식에서, R1은 에틸기 또는 이소프로필기이고, R2는 치환되거나 치환되지 않은 페닐셀레네닐기로서 치환기로는 C1∼C3의 알킬기 및 할로겐 원자 중에서 선택된 하나 또는 그 이상의 것이고, R3은 수소원자, C1∼C3의 알킬기, C1∼C3의 하이드록시알킬기, 아실옥시알킬기 또는 치환되거나 치환되지 않은 페닐기로서 치환기로는 C1∼C3의 알킬기, C1∼C3의 알콕시기 또는 할로겐 원자이고, X는 산소원자 또는 황원자이다.In the above formula, R 1 is an ethyl group or isopropyl group, R 2 is a substituted or unsubstituted phenyl selenenyl group, and the substituent is one or more selected from C 1 to C 3 alkyl group and halogen atom, R 3 is hydrogen Examples of the atom, C 1 -C 3 alkyl group, C 1 -C 3 hydroxyalkyl group, acyloxyalkyl group or substituted or unsubstituted phenyl group include C 1 -C 3 alkyl group and C 1 -C 3 alkoxy group Or a halogen atom, X is an oxygen atom or a sulfur atom.

Description

피리미딘 아사이클로뉴클레오시드 유도체Pyrimidine Acyclonucleoside Derivatives

본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음As this is a public information case, the full text was not included.

Claims (8)

다음 구조식(Ⅰ)로 표시되는 피리미딘 아사이클로뉴클레오시드 유도체 및 이들의 약제학적으로 허용 가능한 염.A pyrimidine acyclonucleoside derivative represented by the following structural formula (I) and a pharmaceutically acceptable salt thereof. 상기 식에서, R1은 에틸기 또는 이소프로필기이고, R2는 치환되거나 치환되지 않은 페닐셀레네닐기로서 치환기로는 C1∼C3의 알킬기 및 할로겐 원자 중에서 선택된 하나 또는 그 이상의 것이고, R3은 수소원자, C1∼C3의 알킬기, C1∼C3의 하이드록시알킬기, 아실옥시알킬기 또는 치환되거나 치환되지 않은 페닐기로서 치환기로는 C1∼C3의 알킬기, C1∼C3의 알콕시기 또는 할로겐 원자이고, X는 산소원자 또는 황원자이다.In the above formula, R 1 is an ethyl group or isopropyl group, R 2 is a substituted or unsubstituted phenyl selenenyl group, and the substituent is one or more selected from C 1 to C 3 alkyl group and halogen atom, R 3 is hydrogen Examples of the atom, C 1 -C 3 alkyl group, C 1 -C 3 hydroxyalkyl group, acyloxyalkyl group or substituted or unsubstituted phenyl group include C 1 -C 3 alkyl group and C 1 -C 3 alkoxy group Or a halogen atom, X is an oxygen atom or a sulfur atom. 제1항에 있어서, 상기 구조식(Ⅰ)로 표시되는 화합물은 1-부틸-6-[(3,5-디메틸페닐)셀레네닐]-5-에틸우라실 및 이의 약제학적으로 허용 가능한 염.The compound represented by the formula (I) is 1-butyl-6-[(3,5-dimethylphenyl) selenyl] -5-ethyluracil and a pharmaceutically acceptable salt thereof. 제1항에 있어서, 상기 구조식(Ⅰ)로 표시되는 화합물은 6-[(3,5-디메틸페닐)셀레네닐]-5-에틸-1-(3-페닐프로필)우라실 및 이의 약제학적으로 허용 가능한 염.According to claim 1, wherein the compound represented by formula (I) is 6-[(3,5-dimethylphenyl) selenyl] -5-ethyl-1- (3-phenylpropyl) uracil and its pharmaceutically acceptable Possible salts. 제1항에 있어서, 상기 구조식(Ⅰ)로 표시되는 화합물은 1-부틸-6-[(3,5-디메틸페닐)셀레네닐]-5-이소프로필우라실 및 이의 약제학적으로 허용 가능한 염.The compound represented by the formula (I) is 1-butyl-6-[(3,5-dimethylphenyl) selenyl] -5-isopropyluracil and a pharmaceutically acceptable salt thereof. 제1항에 있어서, 상기 구조식(Ⅰ)로 표시되는 화합물은 6-[(3,5-디메틸페닐)셀레네닐]-5-이소프로필-1-(3-페닐프로필)우라실 및 이의 약제학적으로 허용 가능한 염.According to claim 1, wherein the compound represented by formula (I) is 6-[(3,5-dimethylphenyl) selenyl] -5-isopropyl-1- (3-phenylpropyl) uracil and pharmaceuticals thereof Acceptable salts. 다음 구조식(Ⅰ)로 표시되는 피리미딘 아사이클로뉴클레오시드 유도체 또는 이들의 약제학적으로 허용가능한 염이 유효성분으로 함유된 항바이러스제.An antiviral agent containing a pyrimidine acyclonucleoside derivative represented by the following structural formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient. 상기 식에서, R1,R2,R3및 X는 상기 제1항에서 정의한 바와 같다.Wherein R 1 , R 2 , R 3 and X are as defined in claim 1 above. 다음 구조식(Ⅰ)로 표시되는 피리미딘 아사이클로뉴클레오시드 유도체 또는 이들의 약제학적으로 허용가능한 염과 약제학적 부형제가 함유된 약제학적 조성물.A pharmaceutical composition containing a pyrimidine acyclonucleoside derivative represented by the following structural formula (I) or a pharmaceutically acceptable salt thereof and a pharmaceutical excipient. 상기 식에서, R1,R2,R3및 X는 상기 제1항에서 정의한 바와 같다.Wherein R 1 , R 2 , R 3 and X are as defined in claim 1 above. 다음 구조식(Ⅰ)로 표시되는 피리미딘 아사이클로뉴클레오시드 유도체 또는 이들의 약제학적으로 허용가능한 염의 바이러스 감염예방 또는 치료제로서의 용도.Use of a pyrimidine acyclonucleoside derivative represented by the following structural formula (I) or a pharmaceutically acceptable salt thereof as an agent for preventing or treating a viral infection. 상기 식에서, R1,R2,R3및 X는 상기 제1항에서 정의한 바와 같다.Wherein R 1 , R 2 , R 3 and X are as defined in claim 1 above. ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.※ Note: The disclosure is based on the initial application.
KR1019940018324A 1994-02-28 1994-07-27 Pyrimidine acyclonucleoside derivatives KR0140021B1 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
KR1019940018324A KR0140021B1 (en) 1994-07-27 1994-07-27 Pyrimidine acyclonucleoside derivatives
EP94922386A EP0748316B1 (en) 1994-02-28 1994-07-29 Pyrimidine acyclonucleoside derivatives
US08/545,682 US5889013A (en) 1994-02-28 1994-07-29 Pyrimidine acyclonucleoside derivatives
JP7507220A JP2683297B2 (en) 1994-02-28 1994-07-29 Pyrimidine acyclonucleoside derivative
BR9408370A BR9408370A (en) 1994-02-28 1994-07-29 Pyrimidine acyclonucleoside derivatives
CA002159817A CA2159817C (en) 1994-02-28 1994-07-29 Pyrimidine acyclonucleoside derivatives
DE69430587T DE69430587T2 (en) 1994-02-28 1994-07-29 PYRIMIDINE-ACYCLONUKLEOSID DERIVATIVES
AU73512/94A AU693107B2 (en) 1994-02-28 1994-07-29 Pyrimidine acyclonucleoside derivatives
PCT/KR1994/000102 WO1995023138A1 (en) 1994-02-28 1994-07-29 Pyrimidine acyclonucleoside derivatives

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1019940018324A KR0140021B1 (en) 1994-07-27 1994-07-27 Pyrimidine acyclonucleoside derivatives

Publications (2)

Publication Number Publication Date
KR960004363A true KR960004363A (en) 1996-02-23
KR0140021B1 KR0140021B1 (en) 1998-06-15

Family

ID=19389044

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019940018324A KR0140021B1 (en) 1994-02-28 1994-07-27 Pyrimidine acyclonucleoside derivatives

Country Status (1)

Country Link
KR (1) KR0140021B1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100344675B1 (en) * 2000-07-06 2002-07-20 세종철관주식회사 The sprayed fire-resistive materials

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100344675B1 (en) * 2000-07-06 2002-07-20 세종철관주식회사 The sprayed fire-resistive materials

Also Published As

Publication number Publication date
KR0140021B1 (en) 1998-06-15

Similar Documents

Publication Publication Date Title
KR950000728A (en) Phosphonate nucleotide ester derivatives
ATE404561T1 (en) NEW ADENINE DERIVATIVES
KR910006277A (en) N-substituted-4-pyrimidineamines and pyrimidinediamines, methods for their preparation and their use as medicaments
DE69331843D1 (en) Xanthine derivatives as antidepressants
KR880013937A (en) Oxetanocin derivatives
EP0322738A3 (en) Benzylidene-malononitrile derivatives for the inhibition of proliferative processes in mammalian cells
KR910009672A (en) Pyridazine derivatives, preparation method thereof and pharmaceutical composition containing the same
KR960007592A (en) New pyrrolocarbazole
KR960022486A (en) New Thiazolidin-4-one Derivatives
KR970706275A (en) A pyrimidinylpyrazole derivative is a pyrimidinyl pyrazole derivative.
KR930016402A (en) Imidazole derivatives having anti-HIV activity
KR880003920A (en) Pyridazinone derivatives
NO177995C (en) Analogous process for the preparation of therapeutically active 1,3-dioxane derivatives
KR920007995A (en) Benzamide derivatives
DK601683A (en) DIALKYLAMINOALCOXYBENZYL ALCOHOL DERIVATIVES
KR960004363A (en) Pyrimidine Acyclonucleoside Derivatives
KR900012925A (en) Indole derivatives
MX9206930A (en) NEW COMPOUNDS
KR920012100A (en) Bisphosphonic acid derivatives, their preparation and uses
FI883484A0 (en) BENZIMIDAZOLDERIVAT, DERAS FRAMSTAELLNING OCH ANVAENDNING VID TERAPI.
KR950025044A (en) Pyrimidine Acyclonucleoside Derivatives
KR890009890A (en) Acyl Derivatives of Hydroxy Pyrimidine
KR910004621A (en) New compounds
KR900700104A (en) Anti-anxiety
KR950011530A (en) Cyclopropane derivatives and antiviral agents containing them

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20040225

Year of fee payment: 7

LAPS Lapse due to unpaid annual fee